PMID- 31850176
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 12
IP  - 12
DP  - 2019
TI  - Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.
PG  - 1898-1907
LID - 10.18240/ijo.2019.12.13 [doi]
AB  - AIM: To evaluate the relative efficacy and safety of besifloxacin for treatment 
      of acute bacterial conjunctivitis. METHODS: A comprehensive search in PubMed, 
      EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for 
      randomized controlled trials (RCTs) comparing besifloxacin with other treatments 
      or placebo. The primary outcome measures were clinical resolution, rates of 
      bacterial eradication, individual clinical outcomes, cure rates, and bacterial 
      eradication rates of different kinds of pathogens. Safety outcomes were the 
      number of adverse effects (AEs). The final search was performed on August 2018. 
      RESULTS: Six RCTs were included. Four studies compared the efficacy and safety of 
      besifloxacin with placebo, 1 study compared besifloxacin with moxifloxacin, and 1 
      study compared besifloxacin with gatifloxacin. A total of 2780 patients met the 
      inclusion criteria. Besifloxacin presented higher efficacy and safety than did 
      placebo in clinical resolution, rates of bacterial eradication, individual 
      clinical outcomes, cure rates, bacterial eradication rates of different kinds of 
      pathogens and the number of AEs. There was no significant difference between 
      besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned 
      above. CONCLUSION: Besifloxacin is highly effective and safe for treatment of 
      acute bacterial conjunctivitis. Further comparative trials regarding the effect 
      of besifloxacin for treatment of acute bacterial conjunctivitis will aid in 
      treatment decisions.
CI  - International Journal of Ophthalmology Press.
FAU - Wang, Jun-Jie
AU  - Wang JJ
AD  - Changzhi Medical College, Changzhi 046000, Shanxi Province, China.
FAU - Gao, Xin-Yi
AU  - Gao XY
AD  - Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren 
      Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710004, Shaanxi 
      Province, China.
FAU - Li, Hong-Zhuo
AU  - Li HZ
AD  - Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi 
      Province, China.
FAU - Du, Shan-Shuang
AU  - Du SS
AD  - Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren 
      Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710004, Shaanxi 
      Province, China.
LA  - eng
PT  - Journal Article
DEP - 20191218
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC6901884
OTO - NOTNLM
OT  - Meta-analysis
OT  - acute bacterial conjunctivitis
OT  - besifloxacin
OT  - randomized controlled trials
EDAT- 2019/12/19 06:00
MHDA- 2019/12/19 06:01
PMCR- 2019/12/18
CRDT- 2019/12/19 06:00
PHST- 2018/08/18 00:00 [received]
PHST- 2019/09/25 00:00 [accepted]
PHST- 2019/12/19 06:00 [entrez]
PHST- 2019/12/19 06:00 [pubmed]
PHST- 2019/12/19 06:01 [medline]
PHST- 2019/12/18 00:00 [pmc-release]
AID - ijo-12-12-1898 [pii]
AID - 10.18240/ijo.2019.12.13 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2019 Dec 18;12(12):1898-1907. doi: 10.18240/ijo.2019.12.13. 
      eCollection 2019.